Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 18/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522998 | 1.00 | PTK2 (0.53) | PTK2EGFRROS1ALK | |
| SCHEMBL1674400 | 0.88 | PTK2 (0.54) | PTK2EGFR | |
| SCHEMBL22635675 | 0.86 | PTK2 (0.51) | PTK2 | |
| SCHEMBL1674030 | 0.86 | PTK2 (0.67) | PTK2EGFRROS1 | |
| SCHEMBL1674306 | 0.82 | PTK2 (0.57) | PTK2ROS1 | |
| SCHEMBL29523375 | 0.82 | PTK2 (0.57) | PTK2ROS1 | |
| SCHEMBL22022730 | 0.79 | PTK2 (0.49) | PTK2ROS1 | |
| SCHEMBL1674340 | 0.79 | PTK2 (0.54) | PTK2ROS1 | |
| SCHEMBL29523436 | 0.79 | PTK2 (0.54) | PTK2ROS1 | |
| SCHEMBL1674261 | 0.78 | PTK2 (0.51) | PTK2ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | claimed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | claimed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | claimed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | claimed |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2024-04-30 | — | — | US | claimed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | claimed |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-10-06 | — | — | US | claimed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | claimed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | claimed |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-07-20 | — | — | US | claimed |
| US-20180185372-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2018-07-05 | — | — | US | claimed |
| US-9499560-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2016-11-22 | — | — | US | claimed |
| US-9089574-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2015-07-28 | — | — | US | claimed |
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-11-06 | — | — | US | claimed |
| EP-2785184-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | Emory University (US) | 2014-10-08 | — | — | EP | claimed |
| US-8765755-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD. (AU) | 2014-07-01 | — | — | US | claimed |
| WO-2013082476-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2013-06-06 | — | — | WO | claimed |
| US-20130090336-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-04-11 | — | — | US | claimed |
| US-8354408-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-01-15 | — | — | US | claimed |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-04-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PTK2 1835/4885EGFR 3647/4885ROS1 1857/4885 |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PTK2 2303/4885EGFR 3647/4885ROS1 1357/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PTK2 2303/4885EGFR 3647/4885ROS1 1357/4885 |
| US-20130090336-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | JAK2, JAK3, JAK1 | PTK2 220/4885EGFR 677/4885ROS1 87/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PTK2 418/4885EGFR 3624/4885ROS1 1935/4885 |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | PTK2 418/4885EGFR 3624/4885ROS1 1935/4885 |
| US-20180185372-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PTK2 418/4885EGFR 3624/4885ROS1 1935/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PTK2 1835/4885EGFR 3647/4885ROS1 1857/4885 |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | JAK2, JAK3, JAK1 | PTK2 220/4885EGFR 677/4885ROS1 87/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PTK2 1835/4885EGFR 3647/4885ROS1 1857/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PTK2 418/4885EGFR 3624/4885ROS1 1935/4885 |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PTK2 418/4885EGFR 3624/4885ROS1 1935/4885 |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PTK2 1835/4885EGFR 3647/4885ROS1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.